亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

威尼斯人 医学 阿扎胞苷 队列 骨髓增生异常综合症 低甲基化剂 内科学 癸他滨 临床终点 髓样 肿瘤科 临床试验 白血病 骨髓 慢性淋巴细胞白血病 基因表达 DNA甲基化 基因 生物化学 化学
作者
Guillermo Garcia‐Manero,Aaron D. Goldberg,Eric S. Winer,Jessica K. Altman,Amir T. Fathi,Olatoyosi Odenike,Gail J. Roboz,Kendra Sweet,Crystal Miller,Anders Wennborg,Denice Hickman,Rashmi Kanagal‐Shamanna,Hagop M. Kantarjian,Jeffrey E. Lancet,Rami S. Komrokji,Eyal C. Attar,David A. Sallman
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:10 (4): e272-e283 被引量:74
标识
DOI:10.1016/s2352-3026(22)00403-3
摘要

Summary

Background

TP53-mutated acute myeloid leukaemia is associated with poor outcomes. Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator. We aimed to evaluate the combination of eprenetapopt and venetoclax with or without azacitidine in patients with TP53-mutated acute myeloid leukaemia.

Methods

This phase 1, multicentre, open-label, dose-finding and cohort expansion study was done at eight academic research hospitals in the USA. Inclusion criteria were age of at least 18 years; at least one pathogenic TP53 mutation; treatment-naive acute myeloid leukaemia according to the 2016 WHO classification; an ECOG performance status of 0–2; and a life expectancy of at least 12 weeks. In dose-finding cohort 1 patients received previous therapy with hypomethylating agents for myelodysplastic syndromes. In dose-finding cohort 2, previous use of hypomethylating agents was not permitted. Treatment cycles were 28 days. Patients in cohort 1 received intravenous eprenetapopt 4·5 g/day on days 1–4 and oral venetoclax 400 mg/day on days 1–28; those in cohort 2 also received subcutaneous or intravenous azacitidine 75 mg/m2 on days 1–7. The expansion part of the study proceeded with patients enrolled as in cohort 2. Primary endpoints were safety in all cohorts (assessed in patients receiving at least one dose of assigned treatment) and complete response in the expansion cohort (assessed in patients who completed at least one treatment cycle and had at least one post-treatment clinical response assessment). The trial is registered with ClinicalTrials.gov, NCT04214860, and is complete.

Findings

Between Jan 3, 2020, and July 22, 2021, 49 patients were enrolled across all cohorts. Six patients were initially enrolled into each of dose-finding cohorts 1 and 2; after no dose-limiting toxicities were observed, cohort 2 was expanded to enrol an additional 37 patients. The median age was 67 years (IQR 59–73). 24 (49%) of 49 patients were female and 25 (51%) male, and 40 (82%) were White. At data cutoff (Oct 1, 2021), the median length of follow-up was 9·5 months (IQR 6·1–11·5). No dose-limiting toxicities were recorded and the recommended phase 2 dose for eprenetapopt combinations was 4·5 g/day on days 1–4. Across all patients, adverse events of grade 3 or worse occurring in at least 20% of patients were febrile neutropenia (23 [47%] of 49 patients), thrombocytopenia (18 [37%] patients), leukopenia (12 [25%] patients), and anaemia (11 [22%] patients). Treatment-related serious adverse events occurred in 13 (27%) of 49 patients and there was one (2%) treatment-related death (sepsis). 25 (64%, 95% CI 47–79) of 39 patients had an overall response with eprenetapopt and venetoclax with azacytidine; 15 (38%, 23–55) had a complete response.

Interpretation

Eprenetapopt and venetoclax with azacitidine had an acceptable safety profile and encouraging activity, supporting further frontline evaluation of this combination in the treatment of TP53-mutated acute myeloid leukaemia.

Funding

Aprea Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
4秒前
8952331完成签到 ,获得积分10
4秒前
宁静致远完成签到 ,获得积分10
4秒前
梦寐发布了新的文献求助10
5秒前
pzh完成签到 ,获得积分10
5秒前
AsahiKokura214完成签到,获得积分10
6秒前
6秒前
7秒前
7秒前
标致茈完成签到,获得积分10
8秒前
9秒前
9秒前
朴实香露完成签到 ,获得积分10
11秒前
SciGPT的应助被感性的曼卉采纳,获得30
11秒前
WZT完成签到,获得积分20
11秒前
纯情的阁发布了新的文献求助10
12秒前
12秒前
纯情的阁发布了新的文献求助10
13秒前
纯情的阁发布了新的文献求助10
13秒前
13秒前
烟花的应助被磊4165564采纳,获得10
13秒前
纯情的阁发布了新的文献求助10
13秒前
14秒前
Ava的应助被lysteph采纳,获得10
14秒前
15秒前
15秒前
纯情的阁发布了新的文献求助10
15秒前
16秒前
李志侠完成签到 ,获得积分10
16秒前
研猫发布了新的文献求助10
16秒前
纯情的阁发布了新的文献求助50
16秒前
纯情的阁发布了新的文献求助10
16秒前
纯情的阁发布了新的文献求助10
16秒前
卿卿发布了新的文献求助10
17秒前
纯情的阁发布了新的文献求助10
17秒前
Sweety_完成签到 ,获得积分10
19秒前
纯情的阁发布了新的文献求助10
19秒前
19秒前
纯情的阁发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554315
关于积分的说明 21718840
捐赠科研通 7747967
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551811
邀请新用户注册赠送积分活动 2471239